Tyr574
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr574  -  PDGFRA (human)

Site Information
PDGHEyIyVDPMQLP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448438
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 18 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 ) , mutation of modification site ( 17 , 18 ) , peptide sequencing ( 18 ) , phospho-antibody ( 17 ) , phosphoamino acid analysis ( 18 ) , phosphopeptide mapping ( 18 ) , western blotting ( 17 )
Disease tissue studied:
brain cancer ( 2 , 3 , 7 , 8 , 9 , 14 ) , astrocytoma ( 2 , 3 , 14 ) , glioblastoma ( 7 , 8 , 9 ) , glioma ( 7 , 8 , 9 ) , gastric cancer ( 16 ) , lung cancer ( 4 , 6 ) , non-small cell lung cancer ( 1 , 4 , 6 ) , non-small cell lung adenocarcinoma ( 4 , 6 ) , non-small cell squamous cell lung carcinoma ( 4 , 6 ) , ovarian cancer ( 5 ) , ovarian epithelial carcinoma ( 5 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 1 ) , F cells (fibroblast) ( 17 ) , LN444 (glial) ( 7 , 8 , 9 ) , NCI-H1703 (squamous) ( 4 , 6 , 10 , 11 , 12 , 13 ) , ovary ( 5 ) , PAE (endothelial) ( 18 ) , SNU-1 (gastric) ( 16 ) , U-118MG (glial) ( 2 , 3 , 14 )

Upstream Regulation
Putative in vivo kinases:
PDGFRA (human) ( 18 )
Treatments:
PDGF ( 17 , 18 )

Downstream Regulation
Effects of modification on PDGFRA:
molecular association, regulation ( 18 )
Induce interaction with:
Src (human) ( 18 )

References 

1

Rikova K (2012) CST Curation Set: 16140; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

2

Possemato A (2011) CST Curation Set: 11915; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Possemato A (2011) CST Curation Set: 11916; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

5

Ren H (2010) CST Curation Set: 10132; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411
Curated Info

6

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Tucker M (2009) CST Curation Set: 8070; Year: 2009; Biosample/Treatment: cell line, LN444/PDGF; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Tucker M (2009) CST Curation Set: 8063; Year: 2009; Biosample/Treatment: cell line, LN444/PDGF; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Tucker M (2009) CST Curation Set: 8062; Year: 2009; Biosample/Treatment: cell line, LN444/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Possemato A (2009) CST Curation Set: 7155; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Possemato A (2009) CST Curation Set: 7157; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Possemato A (2009) CST Curation Set: 7156; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Possemato A (2009) CST Curation Set: 7154; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Tucker M (2009) CST Curation Set: 5978; Year: 2009; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-203
18083107   Curated Info

16

Guo A (2006) CST Curation Set: 1628; Year: 2006; Biosample/Treatment: cell line, SNU-1/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Ikuno Y, Leong FL, Kazlauskas A (2002) PI3K and PLCgamma play a central role in experimental PVR. Invest Ophthalmol Vis Sci 43, 483-9
11818394   Curated Info

18

Hooshmand-Rad R, Yokote K, Heldin CH, Claesson-Welsh L (1998) PDGF alpha-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells. J Cell Sci 111 ( Pt 5), 607-14
9454734   Curated Info